Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : May Buy Low and Smart in Generics Gambit

share with twitter share with LinkedIn share with facebook
share via e-mail
07/27/2019 | 01:37pm EDT

By Charley Grant

Pfizer Chief Executive Albert Bourla knows a deal when he sees one.

The pharmaceuticals giant is in talks to merge its off-patent drugs business with generics manufacturer Mylan, The Wall Street Journal reported. The companies have discussed a stock deal in which Pfizer shareholders would own the majority of the new company, which would include well-known drugs like EpiPen, Lipitor and Viagra.

The generics industry has hit a rough patch: Consolidation of major drug-buying consortia has led to falling prices for manufacturers in the U.S. That has eroded revenues and led to severe share-price declines for companies in the sector. Adding scale is one possible way to contend with those harsh realities. Mylan also has a large presence overseas and a well-regarded pipeline of new products, such as cheaper versions of expensive biologic medications.

Should the deal reach the finish line, it certainly helps that Mr. Bourla is buying low. Mylan's shares were down more than 75% from their 2015 peak as of Friday -- par for the course in the beleaguered sector. Over that time Pfizer's shares are up by more than 20%.

Familiarity increases the odds of success. The companies already work together on manufacturing EpiPen, which should limit headaches from integrating operations. And while industry sales aren't growing, the generics drugs business still generates significant cash flow. The new company will thus be able to carry significant leverage on its balance sheet. Pfizer plans to issue $12 billion in fresh debt in conjunction with the deal.

Just as importantly for Pfizer, the deal accomplishes a goal that the company has discussed in various forms for years: separating its business of newer drugs with patent protection from its maturing products. Spinning out older drugs may increase the valuation of newer medicines in its portfolio such as the pneumonia vaccine Prevnar 13 or prostate cancer drug Xtandi.

To that end, Pfizer agreed last month to buy cancer specialist Array BioPharma for more than $10 billion and agreed last December to combine its consumer-health business with GlaxoSmithKline and eventually spin it out. A possible deal with Mylan would be entirely consistent with this strategy.

That ought to keep Pfizer shares, which have rallied about 13% over the past year, in healthy spirits.

Write to Charley Grant at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
MYLAN NV 0.11% 18.46 Delayed Quote.-32.63%
PFIZER 0.98% 43.09 Delayed Quote.-1.28%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
07:43aPfizer to Merge Off-Patent Drug Business With Mylan
07:30aMARKET SNAPSHOT: Is The Stock Market Set Up For Another Late-year Nose Dive?
07:29aPFIZER : to absorb Mylan, creating generic giant
07:24aPFIZER : to Merge Off-Patent Drug Business With Mylan
07:18aMYLAN : to combine with Pfizer's off-patent medicines unit
07:16aNEWS HIGHLIGHTS : Top Company News of the Day
07:08aMylan to combine with Pfizer's off-patent medicines unit
07:06aMYLAN : Pfizer posts 30% rise in quarterly profit
07:05aPFIZER : will absorb Mylan, a $10 billion generic pharmaceutical company that is..
07:02aPFIZER : 2Q Earnings Snapshot
More news
Financials (USD)
Sales 2019 53 448 M
EBIT 2019 19 421 M
Net income 2019 12 762 M
Debt 2019 25 930 M
Yield 2019 3,33%
P/E ratio 2019 18,0x
P/E ratio 2020 16,8x
EV / Sales2019 4,96x
EV / Sales2020 4,98x
Capitalization 239 B
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 47,23  $
Last Close Price 43,09  $
Spread / Highest target 27,6%
Spread / Average Target 9,61%
Spread / Lowest Target -4,85%
EPS Revisions
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-1.28%239 227
JOHNSON & JOHNSON1.30%347 095
ROCHE HOLDING LTD.10.70%232 404
ROCHE HOLDING13.03%232 404
NOVARTIS24.44%213 301